MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment; TecDAX) intends to place 384,338 new shares through an accelerated book building process to institutional investors. The Management and Supervisory Boards of MorphoSys AG decided to increase the Company’s equity capital against contribution in cash exempting preemptive rights. WestLB AG acts as Lead Manager of the transaction joined by DZ BANK AG as Co-Lead Manager.
MorphoSys intends to use the issue proceeds to further expand the Company’s research antibody segment, operating under the brand Antibodies Direct, and accelerate external and internal sales growth of the unit.
MorphoSys intends to use the issue proceeds to further expand the Company’s research antibody segment, operating under the brand Antibodies Direct, and accelerate external and internal sales growth of the unit.